MGI Tech and AddLife AB Announce Strategic Collaboration for Expanded Distribution of MGI products* in the Nordic Region

MGI partners with AddLife AB to expand distribution of sequencing products across the Nordic region, strengthening access to advanced genomics technologies.

Stockholm, Sweden, 8 June 2023 – MGI Tech Co., Ltd. (“MGI”), a company committed to developing core tools and technologies to advance the life sciences, is pleased to announce a comprehensive collaboration with AddLife AB, one of Europe’s largest distributors of clinical testing and laboratory equipment, headquartered in Stockholm. This partnership aims to strengthen the distribution of MGI products* across the Nordic region, leverage the strong market presence and expertise of AddLife AB’s Triolab Group subsidiaries, and expand downstream applications into emerging areas such as point-of-care testing (POCT) and remote ultrasound.

Under the agreement, AddLife AB’s four Triolab Group subsidiaries – Triolab Sweden, Triolab Norway, Triolab Denmark (including Iceland) and Triolab Finland – will serve as individual distributors of MGI products* within their respective markets.

“At AddLife, our goal is to meet our customers’ needs at the highest level. Innovation is one of our core values, and the addition of MGI’s product portfolio is a strong complement to our laboratory offering,” said Kai Rantanen, Head of the Diagnostic Business at AddLife AB. “It enables our customers to access some of the most modern and innovative technologies available.”

Duncan Yu, President of MGI, commented, “We are pleased to partner with AddLife AB and its Triolab Group subsidiaries to expand our presence in the Nordic region. AddLife’s extensive distribution network and deep market knowledge, combined with MGI’s advanced sequencing products*, will allow us to better serve healthcare professionals and support improved patient outcomes.”

The collaboration represents an important step in addressing the evolving needs of healthcare providers across the Nordic region. By combining their respective strengths, MGI and AddLife AB aim to accelerate the adoption of advanced sequencing technologies and support the delivery of high-quality patient care.

* Unless otherwise stated, StandardMPS and CoolMPS sequencing reagents, and sequencers designed for use with such reagents, are not available in Germany, Spain, the UK, Sweden, Italy, the Czech Republic, Switzerland and Hong Kong (CoolMPS is available in Hong Kong).

* Products are for Research Use Only. Not for use in diagnostic procedures, unless otherwise specified.